Zhi Tong Cai Jing·2025-11-10 02:24Core Viewpoint - Tiger Medical (300347) reported a mixed performance in its Q3 2025 results, with a slight decline in revenue but a significant increase in net profit, indicating potential recovery in the industry and strong business resilience [1] Financial Performance - For the first three quarters of 2025, the company achieved revenue of 5.026 billion yuan, a year-on-year decrease of 0.82% [1] - The net profit attributable to shareholders for the same period was 1.02 billion yuan, reflecting a year-on-year increase of 25.45% [1] - In Q3 alone, the company recorded revenue of 1.775 billion yuan, which is a year-on-year increase of 3.86% [1] - The net profit for Q3 was 637 million yuan, showing a substantial year-on-year increase of 98.73% [1] Business Segments - The clinical trial and laboratory services segment remained stable, generating revenue of 1.71 billion yuan in H1 2025, which is a 3.1% increase [1] - The SMO (Site Management Organization) business experienced double-digit growth in new orders, contributing to the overall resilience of the company's operations [1] Future Outlook - The company is expected to continue its performance recovery as the industry shows signs of improvement and order prices stabilize [1]